Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiac disorder signs and symptoms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    40 result(s) found for: Cardiac disorder signs and symptoms. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-000805-27 Sponsor Protocol Number: MEIN/10/Ran-Did/001 Start Date*: 2012-10-23
    Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg
    Full Title: Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction
    Medical condition: Heart failure patients with preserved ejection fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003676-12 Sponsor Protocol Number: ATH3G10-006 Start Date*: 2018-12-17
    Sponsor Name:Athera Biotechnologies AB
    Full Title: A phase IIa, placebo-controlled, double blind, randomised multicentre pilot study to investigate the efficacy, safety and tolerability of the monoclonal antibody ATH3G10 in patients with ST-elevati...
    Medical condition: Treatment of ST-elevated myocardial infarction (STEMI) after percutaneous intervention (PCI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    20.0 10007541 - Cardiac disorders 10064346 STEMI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003865-11 Sponsor Protocol Number: NEOD001-CL002 Start Date*: 2015-11-27
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai...
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000713-32 Sponsor Protocol Number: CAEL101-302 Start Date*: 2021-02-09
    Sponsor Name:Caelum Biosciences, Inc.
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc...
    Medical condition: stage IIIa cardiac AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) PL (Trial now transitioned) BE (Completed) IT (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001375-11 Sponsor Protocol Number: not applicable Start Date*: 2007-05-16
    Sponsor Name:
    Full Title: Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease Long-term follow-up of patients receiving commercially available Myozyme
    Medical condition: Pompe disease (glycogen storage disease type II) is a genetic, lysosomal storage disorder with a frequency of 1 in 40.000 newborns. The disease is caused by deficiency of alpha-glucosidase, a lysos...
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004254-28 Sponsor Protocol Number: CAEL101-301 Start Date*: 2021-01-07
    Sponsor Name:Caelum Biosciences, Inc.
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc...
    Medical condition: stage IIIb cardiac AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000740-21 Sponsor Protocol Number: LEX-210 Start Date*: 2022-04-08
    Sponsor Name:Octapharma AG
    Full Title: Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor.
    Medical condition: Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10009731 Coagulation disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003075-12 Sponsor Protocol Number: 290478 Start Date*: Information not available in EudraCT
    Sponsor Name:Department Of Paediatric Cardiology
    Full Title: Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction.
    Medical condition: Duchenne muscular dystrophy is an X-linked inherited disorder which primarily affects skeletal muscle through a mutation in dystrophin which maps to the long arm of the X chromosome (Xp21). Patient...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001637-18 Sponsor Protocol Number: CKI- 302 Start Date*: 2006-11-13
    Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
    Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f...
    Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) CZ (Completed) BE (Completed) DK (Prematurely Ended) GB (Completed) HU (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002639-48 Sponsor Protocol Number: 54767414AMY2009 Start Date*: 2022-07-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
    Medical condition: Amyloid Light Chain Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005992-81 Sponsor Protocol Number: CL-N-CSM-III/01/08 Start Date*: 2011-03-21
    Sponsor Name:Dr. F. Köhler Chemie GmbH
    Full Title: A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N versus Custodiol
    Medical condition: The study population will be selected from both genders with coronary artery disease (CAD) who are to undergo cardiopulmonary bypass for coronary artery bypass surgery. The ratio of incidence for b...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002261-36 Sponsor Protocol Number: CardioPET™P-02 Start Date*: 2012-11-08
    Sponsor Name:FluoroPharma Medical
    Full Title: A Phase II Open-Labeled Study to Evaluate CardioPET™ as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects with Coronary Artery Disease
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010901-35 Sponsor Protocol Number: G83627057 Start Date*: 2010-04-14
    Sponsor Name:Fundación de Investigación Biomédica Hospital La Paz
    Full Title: ESTUDIO ALEATORIZADO Y DOBLE CIEGO CON DOBUTAMINA VERSUS PLACEBO PARA EL TRATAMIENTO DEL BAJO FLUJO EN VENA CAVA SUPERIOR EN RECIÉN NACIDOS DE BAJO PESO: EVALUACIÓN SISTEMÁTICA DE LOS EFECTOS SOBRE...
    Medical condition: BAJO FLUJO EN VENA CAVA SUPERIOR
    Disease: Version SOC Term Classification Code Term Level
    9 10007539 Cardiac disorder signs and symptoms HLGT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001890-83 Sponsor Protocol Number: P03573 Start Date*: 2006-03-09
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Thrombin Receptor Anta...
    Medical condition: Subjects with symptoms of Coronary Heart Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004318-14 Sponsor Protocol Number: NEOD001-201 Start Date*: 2016-06-13
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019243-19 Sponsor Protocol Number: 004-09 Start Date*: 2012-06-18
    Sponsor Name:Angion Biomedica Corp.
    Full Title: Pilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation from Donors after Cardiac Death
    Medical condition: Patients suffering from end-stage renal disease, receiving a donor kidney from donors after cardiac death
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001407-37 Sponsor Protocol Number: CKI- 301 Start Date*: 2007-06-20
    Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
    Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f...
    Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) HU (Completed) IT (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005103-18 Sponsor Protocol Number: NC20971 Start Date*: 2008-03-21
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Synd...
    Medical condition: Stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007649 Cardiovascular disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) SK (Completed) ES (Prematurely Ended) IE (Prematurely Ended) DK (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001989-15 Sponsor Protocol Number: TV48125-MH-40142 Start Date*: 2020-03-27
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of...
    Medical condition: Migraine and major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) FI (Completed) GR (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000037-14 Sponsor Protocol Number: NEOD001-301 Start Date*: 2021-09-01
    Sponsor Name:Prothena Biosciences Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with ...
    Medical condition: AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:38:15 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA